Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL

For the treatment of mature B cell malignancies including chronic lymphocytic leukemia (CLL), the last 5 years has brought major advances in the application of targeted therapies. Whilst monoclonal anti-CD20 agents such as rituximab have a central role in combination with traditional cytotoxic thera...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Rozario, James, Bennett, Samuel K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535706/
https://www.ncbi.nlm.nih.gov/pubmed/31205643
http://dx.doi.org/10.1177/2040620719844697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535706/
https://www.ncbi.nlm.nih.gov/pubmed/31205643
http://dx.doi.org/10.1177/2040620719844697

Ejemplares similares